Aquestive(US:AQST) Globenewswire·2026-01-20 21:38Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Aquestive Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices following a significant stock price drop due to FDA notification of deficiencies in a New Drug Application [1][2]. Investigation Details - On January 9, 2026, Aquestive disclosed that the FDA identified deficiencies in its New Drug Application for Anaphylm™ (epinephrine) Sublingual Film, which is intended for treating severe allergic reactions, including anaphylaxis. This notification has precluded discussions regarding labeling and post-marketing commitments for the product [2]. Next Steps - Investors who purchased or acquired Aquestive shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. The firm offers consultations without any cost or obligation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and consumer protection cases. The firm operates nationwide and handles cases in both federal and state courts [4].